Tadeusz Robak, MD, PhD, of the Medical University of Lodz, Lodz, Poland, provides an overview of the main findings presented at the 2021 virtual international workshop on chronic lymphocytic leukemia (CLL) and discusses highlights from the meeting. Firstly, technological advances have made possible the genomic analysis of CLL cells at the single-cell level. Secondly, clinical trial data has suggested that 17p deletions and TP53 mutations are associated with poor therapeutic outcomes. Lastly, the results from the ALPINE trial (NCT03734016) suggests that the novel BTK inhibitor zanubrutinib is more effective and less toxic than ibrutinib in CLL patients. Novel, non-covalently binding BTK inhibitors such as pirtobrutinib are being actively investigated. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL).